Impact of Utilization Management on Physician Autonomy and Shared Decision-Making in Oncology

EP: 1.Impact of Recent Policies on US Health Care System and Oncology Practice

EP: 2.Bridging Policy Change With Patient Access and Care Delivery in Oncology

EP: 3.Role of Pharmacy Benefit Managers in Oncology

EP: 4.Impact of Utilization Management Policies in Oncology

EP: 5.Challenges of Step Edits in Oncology

EP: 6.Understanding Gaps in Aligning Coverage Policy With Innovation in Oncology

EP: 7.Disconnect Between NCCN Guidelines and Coverage Decisions With BTK Inhibitors in CLL

EP: 8.Impact of Evidence-Coverage Misalignment on Patient Outcomes With BTK Inhibitors in CLL

EP: 9.Using Real-World Evidence of BTK Inhibitors to Inform Coverage Decisions in CLL

EP: 10.Balancing Black Box Warnings With Real-World Oncology Practice

Now Viewing

EP: 11.Impact of Utilization Management on Physician Autonomy and Shared Decision-Making in Oncology

EP: 12.Shaping Oncology Policy Through Access and Safety Considerations

EP: 13.Impact of Inflation Reduction Act and the Drug Price Negotiation Program in Oncology

EP: 14.Implications of IRA Drug Pricing Negotiations on BTK Inhibitors in CLL

EP: 15.The Future of Oncology Research in a Shifting Policy Landscape

Panelists discuss how increasing utilization management oversight affects physician autonomy and the shared decision-making process in oncology. They note that rigid prior authorizations and treatment mandates can undermine patient trust and disrupt the clinician-patient partnership.

Providers often spend significant time justifying care plans already supported by evidence, diverting resources from patient engagement. The discussion highlights the emotional toll of administrative barriers and the resulting fragmentation of care.

Panelists propose reforms such as transparent criteria, real-time electronic authorizations, and clinician-payer advisory boards to restore balance between oversight and professional independence.